Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5641 to 5655 of 7682 results

  1. Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal Pathogen Panel, the FilmArray GI Panel and the Faecal Pathogens B assay.

    Recommendation ID DG26/1 Question Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal

    Research recommendation
    Published
    17 February 2017

  2. Further research is recommended on: The accuracy of EarlyCDT Lung, and the validity of the risk models used to combine EarlyCDT Lung results with the Brock and the Herder risk models. The impact of EarlyCDT Lung on clinical management decisions. A large retrospective audit is recommended to: Understand how patient and nodule characteristics impact on malignancy prevalence and disease progression. Understand current practice regarding clinical management of people with intermediate-risk lung nodules. Determine the clinical consequences of CT surveillance, including the likelihood of disease progression during CT surveillance. Determine the likelihood and impact of unnecessary biopsy or resection of indolent and benign nodules If existing data on these points is limited or not routinely collected, a prospective data collection should be undertaken to obtain it.

    Recommendation ID DG46/01 Question Further research is recommended on: The accuracy of EarlyCDT Lung, and the validity of the risk models

    Research recommendation
    Published
    24 March 2022

  3. Further research is recommended on the diagnostic performance of the TriageTrue high-sensitivity troponin test using samples at point of care.

    Recommendation ID DG40/1 Question Further research is recommended on the diagnostic performance of the TriageTrue high-sensitivity troponin

    Research recommendation
    Published
    26 October 2020

  4. Further research is recommended on:• the impact of LiverMultiScan test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of LiverMultiScan compared with biopsy, or the prognostic ability of LiverMultiScan to predict clinical outcomes (see section 3.19 ).

    Recommendation ID DG50/01 Question Further research is recommended on:• the impact of LiverMultiScan test results on decisions about care

    Research recommendation
    Published
    3 February 2023

  5. Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF ratio), with standard clinical assessment, in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation, who have had a negative PlGF-based test result (Triage PlGF test result of 100 picograms/ml or more; Elecsys immunoassay sFlt 1/PlGF ratio of less than 38) that was used to rule-out pre-eclampsia. This should include:- exploration of the different scenarios in which repeat testing may be indicated- the appropriate intervals between PlGF-based tests- the diagnostic accuracy of PlGF-based testing in women with suspected pre-eclampsia who have previously had 1 or more negative PlGF-based test results.

    Recommendation ID DG23/1 Question Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys

    Research recommendation
    Published
    22 June 2016

  6. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    Recommendation ID DG50/02 Question Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results

    Research recommendation
    Published
    3 February 2023

  7. Further research is recommended on the use of the Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF ratio, with standard clinical assessment, to rule-in pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation. This should specifically investigate how a positive PlGF-based test result (Triage PlGF test result of 12 picograms/ml or less; Elecsys immunoassay sFlt 1/PlGF ratio of greater than 38) used to rule-in pre-eclampsia would affect management decisions on time to delivery and the outcomes associated with this.

    Recommendation ID DG23/2 Question Further research is recommended on the use of the Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF

    Research recommendation
    Published
    22 June 2016

  8. Further research is recommended on using ImmunoCAP ISAC 112 for diagnosing allergy and clinical outcomes associated with using allergy testing for people with allergy that is difficult to diagnose, specifically in people with:- idiopathic anaphylaxis- multiple allergies and multiple sensitisations- plant-derived food allergy- seafood allergy, but who have a positive history and negative diagnostic test results.

    Recommendation ID DG24/2 Question Further research is recommended on using ImmunoCAP ISAC 112 for diagnosing allergy and clinical outcomes

    Research recommendation
    Published
    22 June 2016

  9. Further research is recommended to assess:- inter-observer reproducibility of tests involving ultrasound scans (the ADNEX model and Simple Rules)- changes in clinical management based on test results from the ADNEX model, Overa (MIA2G), ROMA and Simple Rules.

    Recommendation ID DG31/2 Question Further research is recommended to assess:- inter-observer reproducibility of tests involving ultrasound

    Research recommendation
    Published
    18 October 2018

  10. Further research is recommended to assess the diagnostic accuracy of the tests included in this assessment when used in combination; for example sequentially.

    Recommendation ID DG31/3 Question Further research is recommended to assess the diagnostic accuracy of the tests included in this assessment

    Research recommendation
    Published
    18 October 2018

  11. Further research is recommended to determine the impact of MRI fusion biopsy systems compared with cognitive fusion biopsy on the detection of different grades of prostate cancer.

    Recommendation ID DG53/1 Question Further research is recommended to determine the impact of MRI fusion biopsy systems compared with cognitive

    Research recommendation
    Published
    11 July 2023

  12. Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties for esketamine, summarised in section 3.36 .

    Recommendation ID TA854/01 Question Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties

    Research recommendation
    Published
    6 January 2023

  13. Further research is recommended to identify any health conditions or groups of patients that would benefit more from inhaled sedation with Sedaconda ACD-S than from standard care

    Recommendation ID MTG65/01 Question Further research is recommended to identify any health conditions or groups of patients that would

    Research recommendation
    Published
    1 February 2022

  14. Further research is recommended to resolve the uncertainties about the long-term clinical effectiveness of darvadstrocel compared with standard care. In particular, estimates of long-term remission rates (minimum of 2 years' follow-up) in Crohn's disease with perianal fistulas are needed.

    Recommendation ID TA556/1 Question Further research is recommended to resolve the uncertainties about the long-term clinical effectiveness

    Research recommendation
    Published
    19 March 2019

  15. Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.

    Recommendation ID TA404/1 Question Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix

    Research recommendation
    Published
    17 October 2016